MeSH tree: D03.633.100.473.402.613
A study, published in Molecular Psychiatry, led by Prof. Bernard Lerer from the Department of Psychiatry at the Hadassah—Hebrew University Medical Center shows promising results for using psilocybin, a psychedelic compound, ...
Oct 29, 2024
0
79
Monash University researchers have made a breakthrough in the study of psychedelics to treat disorders including major depression, demonstrating that rats given psilocybin exhibit increased optimism over time.
Oct 8, 2024
0
83
Psilocybin, the psychedelic substance found in magic mushrooms, is a promising new treatment for psychiatric disorders, especially depression. The beneficial effects on mood and anxiety of psilocybin are rapid and pronounced ...
Oct 2, 2024
1
33
Body dysmorphic disorder (BDD) is a debilitating mental illness characterized by an obsessive preoccupation with perceived flaws in one's physical appearance. Patients with BDD often have distorted self-image, intrusive thoughts, ...
Sep 24, 2024
0
49
A direct comparison between the experimental psychedelic drug psilocybin and a standard SSRI antidepressant shows similar improvement of depressive symptoms, but that psilocybin offers additional longer-term benefits.
Sep 21, 2024
0
187
In the wake of mounting evidence for the efficacy of psychedelic-assisted therapies, the U.S. Food and Drug Administration (FDA) is considering approving psilocybin, the active ingredient in "magic mushrooms," for treating ...
Sep 13, 2024
0
55
Feeling safe and comfortable are key when discussing your health and well-being with your primary care provider.
Sep 10, 2024
0
27
Depression is one of the most common mental disorders, affecting an estimated 300 million people worldwide. While there are currently numerous pharmacological treatments for depression, how different treatments impact the ...
High doses of psilocybin—the active ingredient in magic mushrooms—appears to have a similar effect on depressive symptoms as the selective serotonin reuptake inhibitor (SSRI) drug escitalopram, suggests a systematic review ...
Aug 21, 2024
0
82
Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company's application for the use of MDMA-assisted therapy in the treatment of post-traumatic stress disorder. ...
Aug 13, 2024
0
34
